Ascom Holding Valuation
Is ASCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ASCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ASCN (CHF7.16) is trading below our estimate of fair value (CHF21.23)
Significantly Below Fair Value: ASCN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ASCN?
Other financial metrics that can be useful for relative valuation.
What is ASCN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 257.16m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.8x |
Enterprise Value/EBITDA | 10.5x |
PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does ASCN's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 22.6x | ||
CLTN COLTENE Holding | 23.5x | 21.0% | CHF 280.3m |
VBSN IVF Hartmann Holding | 20.1x | n/a | CHF 304.8m |
METN Metall Zug | 25.1x | 7.3% | CHF 558.0m |
4820 EM Systems | 21.7x | 10.5% | JP¥43.8b |
ASCN Ascom Holding | 14.8x | 11.5% | CHF 257.2m |
Price-To-Earnings vs Peers: ASCN is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (22.6x).
Price to Earnings Ratio vs Industry
How does ASCN's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Earnings vs Industry: ASCN is good value based on its Price-To-Earnings Ratio (14.8x) compared to the European Healthcare Services industry average (16.4x).
Price to Earnings Ratio vs Fair Ratio
What is ASCN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 14.8x |
Fair PE Ratio | 24.4x |
Price-To-Earnings vs Fair Ratio: ASCN is good value based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (24.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 7.16 | CHF 11.17 +56.0% | 20.1% | CHF 13.00 | CHF 8.00 | n/a | 3 |
Jul ’25 | CHF 7.67 | CHF 12.17 +58.6% | 7.0% | CHF 13.00 | CHF 11.00 | n/a | 3 |
Jun ’25 | CHF 8.11 | CHF 12.17 +50.0% | 7.0% | CHF 13.00 | CHF 11.00 | n/a | 3 |
May ’25 | CHF 7.40 | CHF 12.17 +64.4% | 7.0% | CHF 13.00 | CHF 11.00 | n/a | 3 |
Apr ’25 | CHF 8.23 | CHF 12.17 +47.8% | 7.0% | CHF 13.00 | CHF 11.00 | n/a | 3 |
Mar ’25 | CHF 7.45 | CHF 13.00 +74.5% | 10.9% | CHF 14.00 | CHF 11.00 | n/a | 3 |
Feb ’25 | CHF 7.27 | CHF 13.00 +78.8% | 10.9% | CHF 14.00 | CHF 11.00 | n/a | 3 |
Jan ’25 | CHF 8.22 | CHF 13.00 +58.2% | 10.9% | CHF 14.00 | CHF 11.00 | n/a | 3 |
Dec ’24 | CHF 10.52 | CHF 15.22 +44.6% | 2.0% | CHF 15.65 | CHF 15.00 | n/a | 3 |
Nov ’24 | CHF 9.56 | CHF 15.72 +64.4% | 3.9% | CHF 16.50 | CHF 15.00 | n/a | 3 |
Oct ’24 | CHF 10.40 | CHF 15.72 +51.1% | 3.9% | CHF 16.50 | CHF 15.00 | n/a | 3 |
Sep ’24 | CHF 10.78 | CHF 14.43 +33.9% | 13.6% | CHF 16.50 | CHF 11.80 | n/a | 3 |
Aug ’24 | CHF 11.94 | CHF 13.67 +14.5% | 22.0% | CHF 16.50 | CHF 9.50 | n/a | 3 |
Jul ’24 | CHF 10.92 | CHF 13.67 +25.2% | 22.0% | CHF 16.50 | CHF 9.50 | CHF 7.67 | 3 |
Jun ’24 | CHF 9.73 | CHF 13.67 +40.5% | 22.0% | CHF 16.50 | CHF 9.50 | CHF 8.11 | 3 |
May ’24 | CHF 8.66 | CHF 13.67 +57.8% | 22.0% | CHF 16.50 | CHF 9.50 | CHF 7.40 | 3 |
Apr ’24 | CHF 8.06 | CHF 12.56 +55.9% | 25.7% | CHF 16.50 | CHF 9.25 | CHF 8.23 | 4 |
Mar ’24 | CHF 8.77 | CHF 12.09 +37.8% | 30.7% | CHF 16.50 | CHF 8.10 | CHF 7.45 | 4 |
Feb ’24 | CHF 8.08 | CHF 12.09 +49.6% | 30.7% | CHF 16.50 | CHF 8.10 | CHF 7.27 | 4 |
Jan ’24 | CHF 7.43 | CHF 12.59 +69.4% | 33.1% | CHF 17.00 | CHF 8.10 | CHF 8.22 | 4 |
Dec ’23 | CHF 7.87 | CHF 13.88 +76.3% | 25.5% | CHF 17.00 | CHF 8.10 | CHF 10.52 | 4 |
Nov ’23 | CHF 6.34 | CHF 13.88 +118.8% | 25.5% | CHF 17.00 | CHF 8.10 | CHF 9.56 | 4 |
Oct ’23 | CHF 5.96 | CHF 13.88 +132.8% | 25.5% | CHF 17.00 | CHF 8.10 | CHF 10.40 | 4 |
Sep ’23 | CHF 6.21 | CHF 13.88 +123.4% | 25.5% | CHF 17.00 | CHF 8.10 | CHF 10.78 | 4 |
Aug ’23 | CHF 7.39 | CHF 14.15 +91.5% | 31.1% | CHF 19.00 | CHF 7.20 | CHF 11.94 | 4 |
Jul ’23 | CHF 6.72 | CHF 14.15 +110.6% | 31.1% | CHF 19.00 | CHF 7.20 | CHF 10.92 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.